(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average but	rden					
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Payne Fletcher					2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105					3. Date of Earliest Transaction (Month/Day/Year) 06/27/2022								X_Officer (give title below) Other (specify below) SR VP & Chief Fin. Officer				
(Street) TORONTO, A6 M2J 4R3					4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing/Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City)	(State)	(Zip)		Table I - Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Ye	Execution (ear)		med on Date, if Day/Year)	(Instr. 8)		(4	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) Owned Following			O Fo D	6. Ownership Form: Direct (D)	Beneficial Ownership	
							Coc	le	V A	amount	(A) or (D)	Price		or Indirect (In (I) (Instr. 4)		Instr. 4)	
Reminder: R	deport on a se	parate line for each	class of securities be	II - Deri	vati	ve Securit	ies Acq	Po th cu	ersons nis for urrent , Dispo	m are r ly valid osed of,	not requ I OMB of or Bene	uired to r control n ficially Ov				SEC 1	474 (9-02)
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ersion Date (Month/Day/Year) of rative	Execution Date, if	4. Transaction Code (Instr. 8)		s, calls, warrants, 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date E Expiration (Month/D		xercisable and n Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	V	(A)	(D) Da		e rcisable	Expira Date	ation	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Common Stock	\$ 0.8479	06/27/2022		A		1,000,0	00		(1)	06/26	6/2032	Commo	11.000.000	\$ 0	1,000,000	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Payne Fletcher C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3			SR VP & Chief Fin. Officer					

Signatures

/s/ Janet Clennett as attorney-in-fact for Fletcher Payne	06/28/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) $\frac{1000}{2026}$. The options vest as follows: 50% of the options vest on 6/27/2023; the remaining options will vest in equal annual installments on June 27, 2024, June 27, 2025, and June 27,

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.